A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of AZD2281 Following Single and Multiple Oral Doses in Patients in Japan With Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2016
At a glance
- Drugs Olaparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 06 May 2009 Planned end date changed from 1 Mar 2009 to 1 Mar 2010as reported by ClinicalTrials.gov.
- 10 Feb 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 03 Jan 2008 New trial record.